Guardant Health announced today that it has raised $50 million in Series C funding for its biopsy-free blood cancer screening test Guardant360. This puts the total funding for the medical technology startup at $90 million. Lightspeed Venture Partners led the round, with participation from Formation 8 and existing investors Khosla Ventures and Sequoia Capital. Read More